Accretion Pharmaceuticals, a Gujarat-based pharma manufacturer, concluded its SME IPO with a strong subscription of 7.31 times. The IPO, priced at Rs 96-101 per share, aims to utilize proceeds for capital expenditures and facility upgrades. Despite robust financial growth and international presence, the grey market premium remained flat, indicating market caution ahead of its NSE SME platform listing.
$20 billion of IPOs per year a new normal for India: JP Morgan
Initial public offerings worth USD 20 billion per annum are the “new normal” for India and will become an annualised run rate over the next